Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Janumet, sitagliptin/metformin (MK-0431A) (ONO-5435A)
print preview
bookmark
share with colleague
General Information
Company
Merck & Co. Inc.
Description
Combination of Januvia sitagliptin phosphate plus metformin
Molecular Target
Dipeptidyl peptidase-4 (DPP-4) (CD26)
;
AMP-activated protein kinase (AMPK)
Mechanism of Action
AMP-activated protein kinase (AMPK) activator; Dipeptidyl peptidase-4 (DPP-4) inhibitor
Latest Stage of Development
Marketed
Indication
Diabetes
Partner
Ono Pharmaceutical Co. Ltd.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy